Background
==========

Interleukin-27 (IL-27), which belongs to the IL-12 family, is a newly-discovered protein consisting of 2 subunits, p28 and the Epstein--Barr virus-induced gene 3 protein, and is mainly secreted by activated antigen-presenting cells \[[@b1-medscimonit-22-766],[@b2-medscimonit-22-766]\]. Human *IL-27* gene, located on chromosome 16p11, consists of 5 exons and 4 introns, acting as a mediator between the adaptive and innate immune systems \[[@b3-medscimonit-22-766]\]. As a multifunctional gene, *IL-27* can regulate the proliferation of naive T-cell and plays an effective role in inducing the production of interferon-gamma \[[@b4-medscimonit-22-766],[@b5-medscimonit-22-766]\]. In addition, *IL-27* is also involved in the up-regulation of Th1 initiation and the down-regulation of Th2 factor GATA binding protein 3, and it is linked to inducing tumor-specific antitumor activity, mediated by CD8^+^ T cells \[[@b1-medscimonit-22-766],[@b5-medscimonit-22-766]\]. Mutations of *IL-27* were recently reported to be susceptible to a variety of diseases, such as colorectal cancer, asthma, rheumatoid arthritis, ovarian cancer, Crohn's disease, nasopharyngeal carcinoma, and esophageal cancer \[[@b1-medscimonit-22-766],[@b6-medscimonit-22-766],[@b7-medscimonit-22-766]\]. Specifically, according to previous studies, 2 single-nucleotide polymorphisms (SNPs) of *IL-27*, 964A/G (rs153109) and 4730 T/C (rs181206), are commonly found to be associated with various diseases \[[@b6-medscimonit-22-766],[@b8-medscimonit-22-766]\]. For instance, a previous study investigated the association of *IL-27* gene polymorphism with Crohn's disease (CD) risk in a Chinese Han population found remarkable association between *IL-27* rs153109 and rs181206 polymorphisms and CD risks \[[@b8-medscimonit-22-766]\]. Moreover, previous studies also found that rs153109 polymorphism may be a protective factor for breast cancer in premenopausal women and is associated with decreased risk of lymph node metastasis in papillary thyroid cancer \[[@b9-medscimonit-22-766],[@b10-medscimonit-22-766]\]. Through the promotion of pro-inflammatory immune response, polymorphisms rs153109 and rs181206 of *IL-27* reduce or delay common antitumor activities responded to by Th1 cytotoxic, increasing the susceptibility to diseases \[[@b7-medscimonit-22-766],[@b11-medscimonit-22-766],[@b12-medscimonit-22-766]\]. Therefore, *IL-27* could be regarded as a candidate gene related to diverse diseases. Previous studies have also shown that variants of *IL-27* are closely correlated with diseases, including numerous common cancers, such as colorectal cancer, nasopharyngeal carcinoma, and ovarian cancer \[[@b6-medscimonit-22-766],[@b13-medscimonit-22-766]\], while some other studies have presented different results \[[@b14-medscimonit-22-766],[@b15-medscimonit-22-766]\]. Therefore, the current study was performed to investigate the potential relationships between the polymorphisms of *IL-27*, rs153109, and rs181206, and their susceptibility to diseases, and to evaluate the role of *IL-27* as a biomarker for the diagnosis and prognosis of diseases.

Material and Methods
====================

Search strategy
---------------

Potential studies were retrieved by a thorough literature search, with language restricted to English or Chinese, in the computerized bibliographic databases MEDLINE, Science Citation Index, PubMed, Embase, Current Contents Index, Chinese Biomedical, Chinese Journal Full-Text, and the Weipu Journal (last updated search was October 2014). We used the following highly sensitive search strategy: ("Interleukin-27" or "Interleukin 27" or "IL 27" or "IL-27" or "IL27") and ("Polymorphism, Genetic" or "polymorphism" or "polymorphisms" or "variants" or "SNP" or "mutation" or "genetic variants"). A manual search was also conducted to find other studies.

Inclusion and exclusion criteria
--------------------------------

Retrieved studies were assessed based on the following criteria: (1) studies published in peer-reviewed journal and conducted in human populations; (2) case-control studies investigating the association between SNPs in *IL-27* (rs153109 A\>G or rs181206 T\>C) and susceptibility and human diseases; (3) patients were confirmed by the diagnostic criteria for each disease type; (4) provided sufficient original data on the genotype frequencies of polymorphisms within the *IL-27* genes; (5) genotype frequencies of *IL-27* met Hardy-Weinberg equilibrium (HWE); (6) studies with overlapping data were only enrolled once. The exclusion criteria were: (1) failed to meet the criteria for study inclusion; (2) letters, abstracts, meta-analysis, reviews, or proceedings; (3) unpublished data; (4) studies without extractable and numerical data; (5) Caucasian population.

Study quality and data extraction
---------------------------------

Newcastle-Ottawa Scale (NOS) criteria were applied to assess the methodological quality of all eligible trials \[[@b16-medscimonit-22-766]\]. These 3 perspectives were independently scored by 2 reviewers: (1) subject selection: 0\~4; (2) subject comparability: 0\~2; (3) clinical outcome: 0\~3. Study with NOS scores ≥7 were considered as good quality (range, 0\~9). Following descriptive information were collected including author name, publication year, journal name, country, detection method, population, language, diseases types, SNP, genotype frequencies, allele frequencies, HWE test, and confirmation of diagnosis. Disagreements during the study inclusion process were settled through consultation with another reviewer.

Statistical analysis
--------------------

The effect size, as represented by the unadjusted odds ratios (ORs) for the presence of the SNP in *IL-27* in patients and controls, was calculated. A 95% confidence interval (95%CI) was tested for the pooled OR using *Z* test. The summarized ORs were performed for the comparisons in allele model (W allele *vs.* M allele), dominant model (WW + WM *vs.* MM), recessive model (WW *vs.* WM + MM), homozygous model (WW *vs.* MM), and heterozygous model (WW *vs.* WM). Cochran's *Q*-statistic and *I*^2^ tests were carried out to identify the heterogeneity among included trials \[[@b17-medscimonit-22-766]\]. Subgroup analyses were also conducted to clarify the substantial heterogeneity. Additionally, the effect of each single study on the overall estimate was determined by application of one-way sensitivity analysis. Further, Egger's linear regression test and funnel plot were employed to inspect the presence of publication bias \[[@b18-medscimonit-22-766],[@b19-medscimonit-22-766]\]. Data analyses were performed utilizing STATA software (Version 12.0, Stata Corp., College Station, TX, USA).

Results
=======

Description of included studies
-------------------------------

The initial search resulted in a total of 46 potentially eligible articles. After the removal of 1 duplicated study and 16 irrelevant articles, 29 articles remained for further review. Subsequently, 11 articles were regarded as unsuitable and were removed, and 18 articles included qualitative analysis were left. In addition, another study was removed due to absence of data integrity. Finally, 17 case-control studies including 4185 patients and 4077 controls were incorporated into the current analysis \[[@b1-medscimonit-22-766],[@b4-medscimonit-22-766]--[@b7-medscimonit-22-766],[@b11-medscimonit-22-766]--[@b15-medscimonit-22-766],[@b20-medscimonit-22-766]--[@b26-medscimonit-22-766]\]. A flow diagram of study selection progress is displayed in [Figure 1](#f1-medscimonit-22-766){ref-type="fig"}. As for the diseases involved in the included studies, there were 16 diseases, including rheumatoid arthritis (RA) (Chen S, 2014), ovarian cancer (OC) (Zhang Z), CD (Lin XY), immune thrombocytopenia (ITP) (Zhao HF), chronic hepatitis B (CHB) (Peng QL-a), hepatitis B virus (HBV)-related liver cirrhosis (LC) (Peng QL-b), Hepatocellular carcinoma (HCC) (Peng QL-c), nasopharyngeal carcinoma (NPC) (Pan GG), colorectal cancer (CRC) (Guo JY and Huang ZQ), Asthma (Qiu RF and Chen S, 2012), esophageal cancer (EC) (Tao YP), systemic lupus erythematosus (SLE) (Lan Y), HBV (Zhu CL), Tuberculosis (TB) (Zhan YZ), Glioma (Zhao B), and chronic obstructive pulmonary disease (COPD) (Huang N).

When focused on the SNPs information, 9 studies analyzed rs153109 A\>G and rs181206 T\>C SNPs, (Lin XY, Chen S, 2014, Chen S, 2012, Tao YP, Huang ZQ, Zhao B, Li CS, Pan GG and Huang N) and 8 studies only investigated rs153109 A\>G SNPs (Zhang Z, Zhao HF, Peng QL, Guo JY, Lan Y, Zhu CL, Zhan YZ and Qiu RF). All 17 studies were performed in Asians. Regarding the detection methods, direct sequencing was used in 2 studies \[Chen S (2012) and Chen S (2014)\]; PCR-RFLP was used in 14 studies \[Zhang Z, Zhao HF, Peng QL (rs153109 A\>G), Pan GG, Guo JY, Tao YP, Huang ZQ, Lan Y, Zhun CL, Zhan YZ-a, Zhao B, Qiu RF and Huang N\]; PCR-SSP was used in 2 studies \[Peng QL and Zhan YZ-b\]; PCR-LDR was used in 1 study (Lin XY); and SBE was used in 1 study (Li CS). The basic information for 17 eligible studies is presented in [Table 1](#t1-medscimonit-22-766){ref-type="table"}.

Quantitative data synthesis
---------------------------

In the current study, 2 SNPs (rs153109 A\>G, and rs181206 T\>C) within the *IL-27* gene were identified. Additionally, since significant heterogeneity existed, studies were stratified by disease type. Our results suggested that the carriers of the rs181206 T\>C polymorphism in the *IL-27* gene have an elevated risk of diseases in the allele model (OR=0.76, 95%CI=0.69\~0.84, *P*\<0.001) and dominant model (OR=0.77, 95%CI=0.69\~0.87, *P*\<0.001). With respect to the rs153109 A\>G polymorphism, findings in the present study suggested that the population containing rs153109 A\>G polymorphism was more likely to develop related diseases in comparison to the control group in both the allele model (OR=0.85, 95%CI=0.76\~0.94, *P*=0.002) and the dominant model (OR=0.84, 95%CI=0.71\~0.99, *P*=0.033) ([Figure 2A--2D](#f2-medscimonit-22-766){ref-type="fig"}).

In the disease type-stratified subgroup analysis, our results yielded elevated risk of related diseases in *IL-27* rs181206 T\>C carriers in allele model in the ITP, Asthma, and EC subgroup (ITP: OR=0.69, 95%CI=0.53\~0.88, *P*=0.004; Asthma: OR=0.60, 95%CI=0.41\~0.89, *P*=0.010; EC: OR=0.79, 95%CI=0.64\~0.97, *P*=0.026), but not in RA, CD, NPC, CRC, Glioma, UC, and COPD (all *P* \> 0.05). It has been suggested that subjects with the *IL-27* rs153109 A\>G polymorphism had elevated risk of related diseases in the allele model in the OC, SLE, TB, UC and the COPD subgroups (all *P*\<0.05); but not in the CD, CHB, LC, HCC, NPC, CRC, Asthma, EC, or Glioma subgroups (all *P*\>0.05) ([Figure 3A, 3B](#f3-medscimonit-22-766){ref-type="fig"} and [Table 2](#t2-medscimonit-22-766){ref-type="table"}).

We further conducted sensitivity analyses to determine whether review conclusions were affected by any single study. We found that no single study affected the pooled ORs in the current meta-analysis ([Figure 4A--4D](#f4-medscimonit-22-766){ref-type="fig"}). Finally, Egger's regression test implied no asymmetrical distribution in the funnel plot in the rs181206 T\>C (allele model: t=0.08, *P*=0.934; dominant model: t=0.15, *P*=0.883, respectively), and the rs153109 A\>G (allele model: t=0.05, *P*=0.961; dominant model: t=−0.44, *P*=0.667, respectively) ([Figure 5A--5D](#f5-medscimonit-22-766){ref-type="fig"}).

Discussion
==========

A meta-analysis was performed to explore the relationship between polymorphisms of rs153109 (−964 A/G), rs181206 (4730 T/C) in the *IL-27* gene and the development of some inflammatory, autoimmune diseases and cancer. The results of our meta-analysis demonstrated the relationship of the polymorphisms of rs153109 with the pathogenesis of TB, SLE, UC, COPD, and OC and the connection between polymorphisms of rs181206 with the development of ITP, asthma, and EC. Interleukins promote the development and differentiation of T and B lymphocytes, and hematopoietic cells and are involved in immune system function. Increasing data demonstrate that many human diseases may be associated with the gene polymorphisms of *IL-8, IL-6, IL-1*β*,* and *IL-10* \[[@b27-medscimonit-22-766]--[@b30-medscimonit-22-766]\]. IL-27, a heterodimeric cytokine, consists of the Epstein Barr-virus-induced gene 3, which contains 2 cytokine-binding domains without membrane anchoring motifs and a cytoplasmic tail, having no its own activity and IL-27p28, a predicted cytokine-like protein with 4-alpha helix bundle, forming functional IL-27 \[[@b31-medscimonit-22-766]\]. IL-27, structurally linked with IL-12 and IL-23, engages a receptor of gp130 and the IL-27Rα, which could activate JAK-signal transducer, an activator of transcription and signaling of mitogen-activated protein kinase \[[@b32-medscimonit-22-766]\]. Through promoting the proliferation of T cell and inducing the production of IFN-γ, IL-27 could act as a TH1 type immune response initiator to take part in host defense against pathogen infections and by suppressing effector and memory T cells expansion and inhibiting cytokine secretion, such as TH1, TH2, and TH17, IL-27, which could also act as an immune inflammatory response attenuator to participate in autoimmunity and infection \[[@b33-medscimonit-22-766]\]. IL-27 also induces tumor-specific antitumor activity, mainly by mediating CD8^+^ T cells with enhancement of CTL activity \[[@b11-medscimonit-22-766]\]. It has been reported that IL-27 is connected with inflammatory and autoimmunity diseases and cancer by modulating Tr-1 cells, Tfh, Treg, and other linked immune cells \[[@b34-medscimonit-22-766]\]. Human *IL-27* gene consists of 5 exons, with rs153109 (−964 A/G), rs181206 (4730 T/C) in the promoter of the *IL-27* gene, which could modulate the expression of IL-27 \[[@b6-medscimonit-22-766]\]. Recently, increasing data found that the rs153109 and rs181206 in *IL-27* gene was associated with risk of asthma \[[@b35-medscimonit-22-766]\]. One mechanism could be the polymorphism of rs153109 of the *IL-27* gene just located in the disease-related locus such as UC and CD, suggesting the association with susceptibility to UC and CD \[[@b5-medscimonit-22-766]\]. Another possible mechanism is that different haplotypes and genotypes of the *IL-27* gene may vary in the expression of IL-27, thus playing various roles in the progression of diseases. It was reported that the *IL-27* 964A/G AG genotype and *IL-27* gene TGG haplotype could protect the progression of COPD, while the G allele in *IL-27* 964A/G might also be related to the susceptibility to SLE \[[@b21-medscimonit-22-766]\]. rs153109 is located in the promoter of *IL-27,* which could play a crucial role in initiating the transcription and protein expression regulation, which was associated with epithelial ovarian cancer \[[@b7-medscimonit-22-766]\]. In addition, *IL-27* could trigger the proliferation of naive T-cells and implicated in the development of EC by inhibiting Th1 cytotoxic response to the delayed acquisition of common antitumor activities \[[@b6-medscimonit-22-766]\]. We conclude from the above analysis that the polymorphisms of *IL-27* participate in many diseases because of the location in the disease-related area and the promoter, and different genotypes and haplotypes of *IL-27*. Zhan et al. found that rs153109 variant was susceptible with tuberculosis due to the decreased IFN-γ and IL-12 secretion to improve the survival of tubercle bacilli in the macrophages to abate the immune reaction to tubercle bacilli (*<http://www.cabdirect.org/abstracts/20103084194.html;jsessionid=43F95B13D04B3CF47861675891E2BCC6>*).

Considering that possible related influential factors may influence the link of rs153109 and rs181206 in *IL-27* gene polymorphisms and the development of diseases, we conducted a stratified analysis based on different diseases and detection methods. Subgroup analysis of different diseases show that the *IL-27* gene polymorphisms are related with specific diseases, such as ITP, OC, TB, CD, UC, asthma, EC, and COPD, which may due to different pathogenesis of different diseases. In conclusion, our results are consistent with other studies reporting that the polymorphisms of rs153109 and rs181206 in the *IL-27* gene have a close relationship with many diseases, suggesting the *IL-27* gene polymorphisms may be important in disease diagnosis and prognosis.

Some limitations of our study need to be noted. Firstly, only 2 SNPs (rs153109 and rs181206), widely discussed in various research, were investigated in our study. Additional genomic *loci* (such as rs17855750) should be covered in larger samples and with a broader coverage of genetic variation across the human genome \[[@b33-medscimonit-22-766]\]. Moreover, although the current study covers a great range of human diseases in Asian populations, the sample size for each disease was rather limited. Finally, further investigations to identify *IL-27* rs153109 and rs181206 polymorphisms with human diseases are needed to validate and confirm our results.

Conclusions
===========

Taken together, our findings suggest that the genetic polymorphism of *IL-27* rs153109 and rs181206 may be involved in the progression of human cancers and diseases, especially of TB, UC, COPD, OC, and ITP. Clinical studies and functional analyses are required to investigate the mechanisms underlying the association of other genomic *loci* in the *IL-27* gene or the role of the IL-12 cytokine family with the risk of human cancers and diseases.
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###### 

Characteristics of included studies in this meta-analysis.

  First author                              Year   Country   Disease type   Number    Gender (M/F)   Age (years)   Genotyping method   SNP             NOS score                                                        
  ----------------------------------------- ------ --------- -------------- --------- -------------- ------------- ------------------- --------------- ------------- ------------------- ------------------------------ ---
  Chen S \[[@b14-medscimonit-22-766]\]      2014   China     RA             103       104            28/75         43/61               40 (40\~76)     57 (35\~71)   Direct sequencing   rs153109 A\>G, rs181206 T\>C   7
  Zhang Z \[[@b7-medscimonit-22-766]\]      2014   China     OC             229       320            0/229         0/320               48.9±10.8       48.3±10.1     PCR-RFLP            rs153109 A\>G                  8
  Lin XY \[[@b15-medscimonit-22-766]\]      2013   China     CD             145       238            94/51         155/83              34.3±12.9       36.4±11.8     PCR-LDR             rs153109 A\>G, rs181206 T\>C   7
  Zhao HF \[[@b12-medscimonit-22-766]\]     2013   China     ITP            120       280            50/70         101/179             11 (0.8\~44)    36 (28\~72)   PCR-RFLP            rs153109 A\>G                  7
  ITP                                       210    280       88/122         101/179   36 (17\~78)    36 (28\~72)   PCR-RFLP            rs153109 A\>G   8                                                                
  Peng QL-a \[[@b11-medscimonit-22-766]\]   2013   China     CHB            112       105            85/27         83/22               41.3±11.3       43.2±11.1     PCR-RFLP            rs153109 A\>G                  8
  LC                                        65     105       65/51          83/22     45.6±11.9      43.2±11.1     PCR-RFLP            rs153109 A\>G   7                                                                
  HCC                                       107    105       107/85         83/22     45.4±12.4      43.2±11.1     PCR-RFLP            rs153109 A\>G   7                                                                
  Pan GG \[[@b23-medscimonit-22-766]\]      2012   China     NPC            190       200            135/55        140/60              48.3±8.1        46.5±7.6      PCR-RFLP            rs153109 A\>G, rs181206 T\>C   7
  Guo JY \[[@b20-medscimonit-22-766]\]      2012   China     CRC            170       160            107/63        105/55              52.7±10.3       48.2±9.4      PCR-RFLP            rs153109 A\>G                  7
  Chen S \[[@b13-medscimonit-22-766]\]      2012   China     Asthma         200       111            82/118        69/42               --              --            Direct sequencing   rs153109 A\>G, rs181206 T\>C   7
  Tao YP \[[@b6-medscimonit-22-766]\]       2012   China     EC             426       432            312/114       325/107             --              --            PCR-RFLP            rs153109 A\>G, rs181206 T\>C   7
  Huang ZQ \[[@b1-medscimonit-22-766]\]     2012   China     CRC            410       450            315/95        324/126             57.7±8.3        55.2±7.5      PCR-RFLP            rs153109 A\>G, rs181206 T\>C   8
  Lan Y \[[@b22-medscimonit-22-766]\]       2011   China     SLE            135       150            --            --                  --              --            PCR-RFLP            rs153109 A\>G                  6
  Zhu CL \[[@b32-medscimonit-22-766]\]      2010   China     HBV            168       152            110/58        95/57               56.3±10.4       48.6±18.5     PCR-RFLP            rs153109 A\>G                  7
  Zhan YZ \[[@b25-medscimonit-22-766]\]     2009   China     TB             385       391            243/142       266/125             30.0±15.0       24.0±15.0     PCR-RFLP            rs153109 A\>G                  8
  Zhao B \[[@b4-medscimonit-22-766]\]       2009   China     Glioma         210       220            127/83        125/95              42.3±8.2        40.9±7.1      PCR-RFLP            rs153109 A\>G, rs181206 T\>C   8
  Li CS \[[@b5-medscimonit-22-766]\]        2009   Korea     UC             249       444            179/141       278/166             --              --            SBE                 rs153109 A\>G, rs181206 T\>C   7
  CD                                        71     444       --             --                                                                                                                                          
  Qiu RF \[[@b24-medscimonit-22-766]\]      2008   China     Asthma         360       220            165/195       160/60              --              --            PCR-RFLP            rs153109 A\>G                  7
  Huang N \[[@b21-medscimonit-22-766]\]     2008   China     COPD           120       100            73/47         64/36               59.1±11.0       57.7±10.8     PCR-RFLP            rs153109 A\>G, rs181206 T\>C   6

RA -- rheumatoid arthritis; OC -- ovarian cancer; CD -- Crohn's disease; ITP -- immune thrombocytopenia; T1D -- type 1 diabetes mellitus; CHB -- chronic hepatitis B; LC -- hepatitis B virus (HBV)-related liver cirrhosis; HCC -- hepatocellular carcinoma; NPC -- nasopharyngeal carcinoma; CRC -- colorectal cancer; EC -- esophageal cancer; SLE -- systemic lupus erythematosus; HBV -- hepatitis B virus; TB -- tuberculosis; COPD -- chronic obstructive pulmonary disease; M -- male; F -- female; NOS -- Newcastle-Ottawa Scale; SNP -- single-nucleotide polymorphism; PCR-RFLP -- polymerase chain reaction-restriction fragment length polymorphism; SBE -- single-base extension; PCR-LDR -- polymerase chain reaction-ligase detection reaction; UC -- ulcerative colitis.

###### 

Meta-analysis of the association between *IL-27* polymorphisms and various human diseases.

  Subgroup analysis   W allele *vs.* M (allele model)   WW + WM *vs.* MM (dominant model)   WW *vs.* WM (homozygous model)   WW *vs.* MM (heterozygous model)   WW *vs.* WM + MM (recessive model)                                                                                                  
  ------------------- --------------------------------- ----------------------------------- -------------------------------- ---------------------------------- ------------------------------------ --------- ------ ------------- ---------- ------ -------------- --------- ------ ------------- ----------
  **rs181206 T\>C**   0.76                              0.69\~0.84                          \< 0.001                         0.78                               0.69\~0.87                           \<0.001   0.38   0.26\~0.56    \< 0.001   2.16   1.46\~3.21     \<0.001   0.29   0.20\~0.43    \< 0.001
   RA                 0.78                              0.56\~1.10                          0.163                            0.89                               0.59\~1.34                           0.583     0.23   0.07\~0.77    0.017      4.44   1.32\~14.96    0.016     0.15   0.05\~0.51    0.002
   CD                 0.83                              0.58\~1.19                          0.302                            0.83                               0.56\~1.23                           0.348     0.69   0.16\~3.00    0.625      1.22   0.28\~5.43     0.790     0.56   0.13\~2.44    0.442
   ITP                0.69                              0.53\~0.88                          0.004                            0.69                               0.50\~0.94                           0.020     0.34   0.17\~0.70    0.003      2.24   1.08\~4.63     0.030     0.24   0.12\~0.49    \< 0.001
   NPC                0.81                              0.50\~1.31                          0.391                            0.79                               0.48\~1.31                           0.364     --     --            --         --     --             --        --     --            --
   CRC                0.78                              0.61\~1.01                          0.058                            0.78                               0.59\~1.03                           0.081     0.60   0.26\~1.40    0.237      1.27   0.53\~3.07     0.592     0.52   0.23\~1.21    0.130
   Asthma             0.60                              0.41\~0.89                          0.010                            0.68                               0.44\~1.05                           0.082     0.10   0.02\~0.58    0.010      7.86   1.32\~46.63    0.023     0.09   0.02\~0.50    0.006
   EC                 0.79                              0.64\~0.97                          0.026                            0.79                               0.63\~0.99                           0.041     0.14   0.02\~1.11    0.062      5.78   0.70\~48.01    0.104     0.11   0.01\~0.90    0.039
   Glioma             0.84                              0.55\~1.28                          0.408                            0.90                               0.57\~1.42                           0.656     0.11   0.01\~2.13    0.146      8.61   0.45\~164.64   0.153     0.09   0.00\~1.72    0.110
   UC                 0.75                              0.52\~1.09                          0.132                            0.70                               0.47\~1.05                           0.085     1.22   0.27\~5.49    0.798      0.56   0.12\~2.62     0.460     1.04   0.23\~4.67    0.963
   COPD               0.73                              0.37\~1.44                          0.359                            0.70                               0.34\~1.44                           0.336     --     --            --         --     --             --        --     --            --
  **rs153109 A\>G**   0.85                              0.76\~0.94                          0.002                            0.84                               0.71\~0.99                           0.033     0.73   0.60\~0.89    0.002      1.21   0.98\~1.48     0.074     0.78   0.65\~0.93    0.007
   OC                 0.74                              0.57\~0.94                          0.016                            1.04                               0.74\~1.48                           0.810     0.19   0.09\~0.42    \< 0.001   7.39   3.41\~16.04    \<0.001   0.16   0.07\~0.34    \< 0.001
   CD                 0.70                              0.38\~1.29                          0.249                            0.73                               0.30\~1.80                           0.495     0.51   0.17\~1.52    0.227      1.81   1.05\~3.14     0.033     0.58   0.34\~0.98    0.040
   CHB                0.72                              0.51\~1.04                          0.078                            0.62                               0.38\~1.01                           0.056     0.63   0.38\~1.04    0.069      0.99   0.59\~1.64     0.957     0.79   0.49\~1.26    0.313
   LC                 0.79                              0.50\~1.25                          0.320                            0.72                               0.38\~1.34                           0.300     0.70   0.29\~1.73    0.441      1.03   0.42\~2.56     0.945     0.82   0.36\~1.90    0.648
   HCC                0.97                              0.66\~1.43                          0.875                            0.99                               0.57\~1.72                           0.973     0.92   0.42\~2.01    0.843      1.10   0.51\~2.36     0.803     0.92   0.45\~1.86    0.807
   NPC                0.85                              0.63\~1.14                          0.283                            0.82                               0.55\~1.22                           0.334     0.74   0.39\~1.40    0.355      1.14   0.60\~2.16     0.685     0.80   0.44\~1.46    0.475
   CRC                0.97                              0.82\~1.15                          0.736                            1.09                               0.87\~1.38                           0.457     0.83   0.58\~1.19    0.304      1.26   0.58\~2.77     0.559     0.81   0.45\~1.46    0.487
   Asthma             0.95                              0.77\~1.17                          0.599                            0.92                               0.69\~1.22                           0.558     0.94   0.62\~1.44    0.780      1.00   0.66\~1.53     0.993     0.96   0.65\~1.42    0.850
   EC                 0.96                              0.79\~1.17                          0.676                            0.97                               0.73\~1.28                           0.818     0.90   0.59\~1.37    0.623      1.10   0.73\~1.65     0.650     0.91   0.62\~1.33    0.615
   SLE                1.88                              1.23\~2.87                          0.003                            2.00                               1.22\~3.29                           0.006     3.77   0.97\~14.69   0.055      0.49   0.12\~1.99     0.320     3.09   0.80\~11.88   0.101
   TB                 0.77                              0.63\~0.95                          0.014                            0.67                               0.50\~0.89                           0.005     0.70   0.46\~1.05    0.087      0.93   0.62\~1.41     0.746     0.86   0.59\~1.26    0.439
   Glioma             0.91                              0.69\~1.19                          0.481                            0.97                               0.65\~1.43                           0.864     0.77   0.44\~1.35    0.363      1.36   0.79\~2.35     0.272     0.75   0.45\~1.26    0.275
   UC                 0.72                              0.56\~0.92                          0.010                            0.61                               0.45\~0.84                           0.002     0.72   0.40\~1.29    0.264      0.83   0.45\~1.53     0.553     0.88   0.50\~1.57    0.670
   COPD               0.51                              0.34\~0.74                          \< 0.001                         0.32                               0.17\~0.60                           \<0.001   0.24   0.10\~0.56    0.001      1.46   0.69\~3.07     0.324     0.48   0.23\~0.98    0.043

W -- wild allele; M -- mutant allele; WW -- wild homozygote; WM -- heterozygote; MM -- mutant homozygote; RA -- rheumatoid arthritis; OC -- ovarian cancer; CD -- Crohn's disease; ITP -- immune thrombocytopenia; T1D -- type 1 diabetes mellitus; CHB -- chronic hepatitis B; LC -- hepatitis B virus (HBV)-related liver cirrhosis; HCC -- hepatocellular carcinoma; NPC -- nasopharyngeal carcinoma; CRC -- colorectal cancer; EC -- esophageal cancer; SLE -- systemic lupus erythematosus; HBV -- hepatitis B virus; TB -- tuberculosis; IBD -- inflammatory bowel disease; UC -- ulcerative colitis; COPD -- chronic obstructive pulmonary disease; PCR-RFLP -- polymerase chain reaction-restriction fragment length polymorphism.
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